Pyoderma gangrenosum with response to cyclophosphamide therapy

Crawford, Stanley; Sherman, Roger T.; Favara, Blaise E.

doi:10.1016/s0022-3476(67)80084-2

Cited by 50 publications

(17 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second case initially responded to prednisolone but relapsed when the dose was reduced. Although cyclophosphamide has been reported to be effective in some cases, 5 our patient showed no response. However, minocycline proved valuable, as previously reported 6 .…”

Section: Discussioncontrasting

confidence: 78%

Pyoderma gangrenosum of the penis

Farrell

Black

Bracka

et al. 1998

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 78%

Pyoderma gangrenosum of the penis

Farrell

Black

Bracka

et al. 1998

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…However, more severe presentations warrant management with systemic medications. Oral and intravenous medications that have been reported to successfully treat PG (Table SI 1 ) include: azathioprine, corticosteroids, sulfasalazine, dapsone, thalidomide, minocycline, clofazimine, methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, intravenous immune globulin and cyclophosphamide (23,41,(63)(64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78). Of these, corticosteroids and cyclosporine are the best characterized.…”

Section: Traditional Monotherapymentioning

confidence: 99%

Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review

Patel¹,

Fitzmaurice²,

Duong³

et al. 2015

Acta Derm Venerol

105

115

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is an inflammatory disease characterized by painful skin ulcerations with undermined and erythematous borders. The etiology of PG is not well understood, but it is generally considered to be an aberrant immune response characterized by a dermal neutrophilc infiltrate. Given the existence of only a few PG clinical trials, treatment options are largely based upon anecdotal data and small case studies. In addition to classic immunosuppressive medications, PG has been reported to respond well to the anti-TNF agents, infliximab, etanercept, adalimumab. Newer biologics such as ustekinumab (anti-IL-23), ixekizumab (anti-IL-17) and brodalumab (anti-IL-17R) are promising given the effect of IL-17 on neutrophil migration. However, the effectiveness of these newer agents remains to be rigorously evaluated. Multi-drug regimens have not been well described in the literature but are an excellent alternative for patients with refractory disease. Herein, we provide a comprehensive review of the pathophysiology of PG and of the different treatments available for managing PG patients, including the theoretical benefit of initiating multidrug regimens. We also provide one possible treatment algorithm for patients with refractory disease and give examples of refractory PG cases successfully treated with multidrug regimens.

show abstract

“…Systemic medications that have been successful in treating severe PG include corticosteroids, sulfasalazine, dapsone, thalidomide, minocycline, clofazamine, mycophenolate mofetil, cyclosporine, intravenous immunoglobulin (IVIG), cyclophosphamide, and biologic medications (Table 1). [2][3][4][5][6][7][8] Unfortunately, there is no validated outcome measure for studying PG treatments, thus making it difficult to conduct clinical trials. In fact, only a single-controlled clinical trial exists, a phase II randomized, placebo-controlled study to asses the safety and efficacy of infliximab, an antitumor necrosis factor (anti-TNF) monoclonal antibody, for the treatment of PG.…”

Section: Clinical Problem Addressedmentioning

confidence: 99%